congresos y reuniones científicas
Secretory Leukocyte proteinase inhibitor: a biomarker for acute kidney injury has a protective role in kidney transplantion
AMBROSI NELLA; ROCAMORA J; DOTTA A; GUERRIERI DIEGO; CARO FIORELLA; OSELLA F; SALAVERRY JUAN; SANCHEZ F; RIAL MC; INCARDONA CLAUDIO; CASADEI DOMINGO; CHULUYAN EDUARDO
Congreso; 26 INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY; 2016
Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor produced mainly by epithelial cells. It has anti-inflammatory and antimicrobial activity, and enhances wound healing. Recently, it has been proposed that SLPI could be a novel biomarker for acute kidney injury(1). In fact, we have found that kidney transplanted patients had higher serum values compare with healthy donor (p< 0.0001).The aim of the present study was to assess a putative activity of SLPI on human kidney epithelial cells and lymphocyte proliferation. First, the activity of SLPI on kidney epithelial cell apoptosis was determined by in vitro culture human proximal tubular epithelial cell line (HK-2) under serum starving conditions or by treating the cells with FK506, in the presence of SLPI (40 ng/ml). Apoptosis was examined by flow cytometry with annexin V/propidium iodide and MTT assays. Either FK506 or serum starving conditions induced a high degree of apoptosis. However, when cells were incubated with SLPI, the apoptosis induced by both treatments were statistically reduced in both apoptosis assays. Next, lymphocyte proliferation were assessed by culture human peripheral blood mononuclear cells (PBMCs) derived from healthy dnors or kidney transplant patients. Cell proliferation was induced with phytohemagglutinin (PHA), in the presence or absence of SLPI for 5 days. Then cells were labeled with 3H-thymidine, harvested and counted in a beta-counter. Cells derived from either healthy donors or transplanted patients, treated with PHA + SLPI showed lower proliferation index compared with those treated with PHA alone. These results prove that SLPI has a protective role on epithelial kidney cells and favors the immunossupresive activity by decreasing lymphocyte cell proliferation. Furthermore, we can speculate that the objective of high level of SLPI observed in transplant patients tend to both protect the kidney cells from the noxa and control the immune response in order to reduce the kidney injury by the allogeneic immune response.